For the use of a Registered Medical Practitioner or a Hospital or a Laboratory only

Alphadol-C
Alfacalcidol & Calcium Carbonate Capsules

INTRODUCTION

ALPHADOL-C is combination of alfacalcidol which is chemically known as (5Z,7E)-9,10-Seccocholesta-5,7,10(19)-triene-1α,3β-diol and elemental calcium which is calcium carbonate from organic source (oyster shell).

DESCRIPTION

Alphadol-C is a light blue/dark blue, bilayered, oblong shaped, soft gelatin capsule containing off white semi solid mass.

COMPOSITION

Each soft gelatin capsule contains:

- Alfacalcidol BP ......................... 0.25 mcg
- (1α-Hydroxyvitamin D₃)
- Calcium Carbonate (from Oyster Shell)
  equivalent to Elemental Calcium .....200 mg
- Approved colours used in capsule shells

PHARMACOLOGY

Alfacalcidol
Alfacalcidol chemically known as 1α-hydroxyvitamin D₃ is fat soluble and upto 100% absorption normally takes place. After absorption, alfacalcidol is rapidly hydroxylated at 2 position, predominantly in liver although the enzyme is widely distributed in body tissues.¹ Alfacalcidol (1α-hydroxyvitamin D₃) undergoes rapid hepatic conversion to 1,25-dihydroxyvitamin D₃, which acts as a regulator of calcium and phosphate metabolism. Due to this rapid conversion, the therapeutic benefits of alfacalcidol are virtually the same as those of 1,25-dihydroxyvitamin D₃.² The main effects are to increase circulating 1,25-dihydroxyvitamin D₃ levels, and thereby to increase intestinal absorption of calcium and phosphate, promote bone mineralisation, regulate plasma parathyroid hormone levels as well as to decrease bone resorption, with relief from bone and muscle pain.

Elemental Calcium (Calcium Carbonate)

Calcium carbonate is converted to calcium chloride by hydrochloric acid in stomach where 39% of it is absorbed. It is absorbed as free calcium and bicarbonate ions and is not metabolised.
Physiological concentrations of calcium are rightly controlled principally by the effect of parathyroid hormone (PTH), vitamin D and its metabolites and calcitonin on intestinal absorption, deposition in bone and renal excretion.

**RATIONALE OF COMBINATION**
Alfacalcidol increases the intestinal absorption of calcium. If calcium is readily available in the same preparation, much better and proper absorption of calcium will occur. Calcium supplementation along with alfacalcidol has shown to have a beneficial effect in osteoporosis. Calcium supplementation is usually done with 0.5 - 2g per day of calcium carbonate, gluconate, lactate etc. The calcium content of calcium carbonate is 40% and 500 mg calcium carbonate contains 200 mg elemental calcium which is the least recommended dose of calcium. Moreover, the dosage of alfacalcidol will be reduced to some extent. So, this combination is pharmacoeconomic and beneficial for the patient.

**INDICATIONS**
Indicated in osteoporosis, renal bone disease (Renal osteodystrophy), hypoparathyroidism, hyperparathyroidism (with bone disease), rickets and osteomalacia and chronic renal failure and conditions associated with gastric hyperacidity.

**CONTRAINDICATIONS**
Alphadol-C should not be administered in the presence of hypercalcaemia, hyperphosphataemia (except when occurring with hypoparathyroidism) or hypermagnesaemia, renal calculi, nephrolithiasis, Zollinger's Ellison Syndrome, concomitant digoxin therapy.

**WARNINGS**
*Use in pregnancy*
There is insufficient evidence which establishes the safety of alfacalcidol and calcium carbonate use during pregnancy. Animal studies have not revealed any hazard but as with all drugs, alfacalcidol should only be used during pregnancy if treatment is essential and no better alternative is available.

*Use in Breast feeding*
Although not definitely established, it is likely that increased levels of 1,25-dihydroxyvitamin D₃ will be found in the breast milk of mothers treated with alfacalcidol. This might have some influence on calcium metabolism in a breast-fed infant and discontinuation of breast-feeding should be considered. There is no contraindication to the use of calcium carbonate in lactating women.

**PRECAUTIONS**
Alfacalcidol increases the intestinal absorption of calcium and phosphate, serum levels of which should be monitored, particularly in patients with renal failure. Periodic and regular monitoring of calcium, phosphate, alkaline phosphatase, magnesium and creatinine levels as well as other appropriate biochemical parameters should be done. If hypercalcaemia or hypercalciuria occurs, this can be corrected rapidly by stopping treatment until plasma calcium levels return to normal. Alfacalcidol and calcium carbonate may then be restarted at half the last dose used or as per response of the patient. Alfacalcidol and calcium should be administered with caution to patients with hypercalciuria, especially those with a history of renal calculi.

**DRUG INTERACTIONS**
(a) Alfacalcidol
Alfacalcidol / Digitalis Glycosides : Hypercalcaemia in patients taking digitalis preparations may precipitate cardiac arrhythmias. Patients taking digitalis concurrently with alfacalcidol must therefore be closely monitored.
Alfacalcidol/Barbiturates/Enzyme-inducing anticonvulsant Drugs: Patients on barbiturates or other enzyme-inducing anticonvulsants may require an increased dose of alfacalcidol to produce the desired effect.

Alfacalcidol / Drugs Affecting intestinal Absorption: Absorption of alfacalcidol may be impaired by concurrent use of mineral oil (prolonged use), cholestyramine, colestipol, sucralfate or large amounts of aluminium based antacids.

Alfacalcidol / Magnesium: Cautions should be exercised in the use of magnesium based antacids or laxatives for patients taking alfacalcidol who are on chronic renal dialysis. Hypermagnesaemia may occur.

Alfacalcidol / thiazides: The risk of hypercalcaemia is increased in patients taking thiazide diuretics concurrently with alfacalcidol.

Alfacalcidol / Vitamin D and Derivatives: Alfacalcidol is a potent derivative of Vitamin D. Pharmacological doses of Vitamin D and its derivatives should not be given during alfacalcidol treatment because of the possibility of additive effects and an increased risk of hypercalcaemia.

(b) Calcium Carbonate
Calcium carbonate may enhance cardiac effect of digoxin in case of systemic hypercalcaemia. Calcium carbonate may interfere with absorption of concomitantly administered tetracycline\(^3\), and ciprofloxacin\(^4\).

ADVERSE REACTION
Adverse effects generally relate to hypercalcaemia and, in the case of renal impairment, hyperphosphataemia which may be induced by alfacalcidol therapy. In hypercalcaemic dialysis patients, the possibility of calcium influx from the dialysate should be considered. No other side effects associated directly with alfacalcidol therapy have been noted. Constipation may be a problem with calcium carbonate. Systemic alkalosis and hypercalcaemia are well documented.

DOSAGE AND ADMINISTRATION
General
The dosage and administration of Alphadol-C should be adjusted according to the need of the patient.

The initial dosage is:
Adults: 1-2 capsules / day
Elderly patients: 1 capsule /day

The exact dosage in osteoporosis is not defined, however the various clinical studies\(^5,6,7\) have used the dosage of alfacalcidol in range of 0.5 - 1 mcg/day with or without calcium in treatment of osteoporosis.

Not recommended in children
Subsequent dose titration can be done according to the clinical and biochemical response so as to avoid hypercalcaemia.
Most adults respond to doses of 1 to 3 mcg/day of alfacalcidol and 0.25 - 3 gm of calcium carbonate.
Indices of response, in addition to a rise in plasma calcium, may include a progressive reduction in alkaline phosphatase, a reduction in parathyroid hormone levels, an increase in urinary calcium excretion in patients with normal renal function, bone radiography and histological improvements.

OVERDOSAGE
Manifestations: Hypercalcaemia which may manifest clinically as malaise, fatigue, weakness, dizziness, drowsiness, headache, nausea, dry mouth, constipation, diarrhoea, heartburn, vomiting, abdominal pain, gastrointestinal discomfort, muscle pain, bone pain, joint pain, pruritus or palpitations. There are no documented cases of acute overdose of calcium carbonate.

Treatment: Administration of alfacalcidol should be stopped if hypercalcaemia occurs. Severe hypercalcaemia may require treatment with general supportive measures, with intravenous fluids, and if needed, with a loop diuretic or corticosteroids.

In acute overdosage, early treatment with gastric lavage and / or the administration of mineral oil may reduce absorption and promote faecal elimination.
STORAGE INSTRUCTIONS

Store at a temperature below 25° C, protect from light and moisture.

REFERENCES

1. Tuker G III, Gagnon RE and Haussler MR.
   Vitamin D₃ - 25-Hydroxylase. Tissue occurrence and apparant lack of regulation.
2. Zerwekh JE, Brumbagh PF, Haussler DH et al.
   1-alpha-Hydroxyvitamin D₃. An analogue of vitamin D which apparently acts by
   metabolism to 1-alpha- 25-dihydroxyvitamin D₃.
   Biochemistry, 1974; 13:4097-4102.
3. Albert A, Rees CW,
   Avidity of the tetracycline for the cations of metals.
   Nature,1956; 177:433-434
   The influence of chronic administration of calcium carbonate on the bioavailability of oral
   ciprofloxacin.
5. Shiraki M, Ito H and Orimo H.
   The ultra long term treatment of senile osteoporosis with 1-alpha-Hydroxy vitamin D₃.
6. Shiraki M, Orimo H and Ito H
   Long term treatment of post menopausal osteoporosis with active vitamin D₃. 1-alpha-
   Hydroxy cholecalciferol (1αOH D₃) and 1-24-dihydroxycholecalciferol (1,24 (OH)₂D₃).
7. Francis RM, Boyle IT, Moniz C etal.
   A comparison of the effects of alfalcacidol treatment and vitamin D₂ supplementation on
   calcium absorption in elderly women with vertebral fractures.